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ABSTRACT
Introduction Knee osteoarthritis is a leading cause of
disability, resulting in pain and reduced quality of life.
Exercise is the cornerstone of conservative management
but effects are, at best, moderate. Early evidence suggests
that repetitive transcranial magnetic stimulation (rTMS)
applied over the primary motor cortex (M1) may improve
the effect of exercise in knee osteoarthritis. This pilot study
aims to (1) determine the feasibility, safety and participant-
rated response to an intervention adding M1 rTMS to
exercise in knee osteoarthritis; (2) elucidate physiological
mechanisms in response to the intervention; (3) provide
data to conduct a sample size calculation for a fully
powered trial.
Methods and analysis This is a pilot randomised,
assessor-blind, therapist-blind and participant-blind,
sham-controlled trial. Thirty individuals with painful knee
osteoarthritis will be recruited and randomly allocated
to receive either: (1) active rTMS+exercise or (2) sham
rTMS+exercise intervention. Participants will receive
15 min of either active or sham rTMS immediately prior
to 30 min of supervised muscle strengthening exercise
(2×/week, 6 weeks) and complete unsupervised home
exercises. Outcome measures of feasibility, safety, pain,
function and physiological mechanisms will be assessed
before and/or after the intervention. Feasibility and safety
will be analysed using descriptive analysis. Within-group
and between-group comparisons of pain and function will
be conducted to examine trends of efficacy.
Ethics and dissemination This study has been approved
by the University of New South Wales Human Research
Ethics Committee (HC210954). All participants will provide
written informed consent. The study results will be
submitted for peer-reviewed publication.
Trial registration number ACTRN12621001712897p.

INTRODUCTION
Knee osteoarthritis is a leading cause of
global disease burden resulting in significant pain, and reduced quality of life.1 It is

STRENGTHS AND LIMITATIONS OF THIS STUDY
⇒ Randomised, assessor-
blind, therapist-
blind and

participant-blind, sham-controlled study design.
⇒ Provide detailed methodology for collecting data on

the feasibility, safety, analgesic effect and central
mechanisms of combined repetitive transcranial
magnetic stimulation and exercise therapy in knee
osteoarthritis.
⇒ This proof-of-concept study is not powered to determine treatment efficacy.

estimated that 10% of people aged over 60
years experience knee osteoarthritis symptoms,2 resulting in pain and impaired physical function.3 4 Exercise is the cornerstone of
conservative treatment for knee osteoarthritis
and recommended by all international guidelines.5 Although comparable to pharmacological treatments, the effects of exercise are at
best, moderate, for pain and function, and
small for quality of life.5 To optimise patient
outcomes, innovative treatments are needed
to enhance the effects of exercise in knee
osteoarthritis.
Knee osteoarthritis is a well-
defined joint
disorder, yet pain severity does not always
correlate with structural changes observed
on radiographs.6–8 This discrepancy has been
attributed to maladaptive changes of physiological mechanisms involved in central pain
processing.9 For example, ongoing nociceptive input from the affected joint and deficient endogenous pain inhibition are thought
to increase neuronal excitability of central
pain pathways (termed central sensitisation),10 manifesting as pain hypersensitivity.11
Furthermore, altered primary motor cortex
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(M1) function has been implicated in the development of
chronic pain as M1 plays an essential role in motor control
and central pain processing.12 13 For example, M1 organisational changes are associated with poor performance on
knee movement tasks14 and more severe pain is linked to
reduced M1 intracortical excitability15 in people with knee
osteoarthritis. Additionally, quadriceps muscle weakness,
a hallmark of knee osteoarthritis associated with pain and
disability,16 is associated with voluntary activation deficit,
defined as a reduction in neural drive from the central
nervous system to the muscles.17 Reduced M1 excitability
and voluntary activation deficit from M1, implicated in
quadriceps muscle weakness,18 may therefore contribute
to pain and physical impairments in knee osteoarthritis.
Thus, novel treatments simultaneously targeting these
peripheral and central mechanisms could have a beneficial impact on pain and function in knee osteoarthritis.
Repetitive transcranial magnetic stimulation (rTMS), a
safe, painless, non-invasive brain stimulation technique,
has been used to alleviate chronic pain by inducing
neuroplastic changes within M1. Neuroimaging evidence
suggests that rTMS applied over M1 reduces pain by
activating endogenous opioid systems of brain regions
involved in pain processing.19 20 rTMS modulates activity
in both cortical and subcortical regions, either decreasing
(inhibitory, low-
frequency stimulation <1 Hz) or
increasing (excitatory, high-frequency stimulation >5 Hz)
cortical excitability.21 High-
frequency rTMS applied
over M1 has been shown to produce superior analgesic
effects to low-frequency rTMS in chronic pain populations.22 Recent meta-analyses confirmed analgesic effects
favouring high-frequency rTMS for short-term relief in
chronic pain.23 Although a case study reported positive
effects on pain and function,24 clinical trials of rTMS in
knee osteoarthritis are absent.
Exercise is known to exert peripheral and central
effects on pain. Peripherally, exercise improves muscle
strength and coordination and proprioception to
enhance control of the joint, therefore reducing nociceptive input from the affected knee.25 Centrally, exercise activates opiodergic pathways and endogenous pain
control.26 Synergistic intervention simultaneously modulating peripheral (exercise), and central (rTMS and exercise) mechanisms of knee osteoarthritis could produce
greater improvements in pain.27 Thus, combining high-
frequency rTMS over M1 and exercise has the potential
to improve outcomes in knee osteoarthritis beyond what
can be achieved with rTMS or exercise alone. Although
pooled data from a recent meta-analysis in chronic pain
showed a moderate reduction in pain severity favouring
the combined rTMS and exercise intervention,28 no study
has investigated this intervention in knee osteoarthritis. A
proof-of-concept study is needed to determine the feasibility, safety and participant-rated response to intervention and the effects of such an intervention on pain and
central mechanisms.
The aims of this study are to (1) assess the feasibility,
safety and perceived patient response to an intervention
2

adding M1 rTMS to exercise in knee osteoarthritis; (2)
elucidate physiological mechanisms in response to the
intervention and (3) provide data to conduct a sample
size calculation for a fully powered trial.

METHODS AND ANALYSIS
This protocol was prepared according to the Standard
Protocol Items: Recommendations for Interventional
Trials statement (online supplemental table S1).29 The
trial will be reported following the Consolidated Standards
of Reporting Trials statement for non-pharmacological
treatment,30 the Template for Intervention Description
and Replication checklist and guide31 and Consensus on
Exercise Reporting Template.32 It has been prospectively
registered with the Australian and New Zealand Clinical Trials Registry (ACTRN12621001712897p) (online
supplemental table S2).
Trial design
We will conduct a pilot two-arm parallel-group design,
assessor-blind, therapist-blind and participant-blind
randomised controlled trial. The outcome measures will
be assessed at baseline and on treatment completion
(6 weeks postrandomisation). In addition, measures of
pain and function will also be collected 3 months postintervention (figure 1).
Participants
Inclusion criteria for participants are: (1) individuals
aged ≥50 years with knee osteoarthritis based on the American College of Rheumatology Clinical Criteria,33 having
at least one of the following items: stiffness <30 min, crepitus, bony tenderness, bony enlargement, no palpable
warmth; (2) knee pain for ≥3 months and on most days
of the past month; (3) average pain intensity ≥4 on an
11-point Numeric Rating Scale (NRS) in the past week.
Exclusion criteria are: (1) previous knee joint replacement or high tibial osteotomy on the affected side; (2)
knee surgery or joint injection in the past 6 months;
(3) planned surgery in the next 9 months; (4) using
oral corticosteroids currently or in the past 4 weeks; (5)
confirmed diagnosis of systemic arthritis (ie, rheumatoid arthritis); (6) previous knee fracture or malignancy;
(7) other conditions affecting lower limb function; (8)
taking part in any knee strengthening exercise in the past
6 months; (9) any loss of sensation of the affected lower
limb; (10) neurological or psychiatric disorders; (11) use
of neuroactive drugs; (12) contraindications to TMS (ie,
epilepsy, metal implant in the skull) based on the TMS
safety screening questionnaire.34 35
Recruitment
Participants in the community in Sydney, Australia will
be recruited from local arthritis support groups, social
media platforms and healthcare providers (medical
practitioners, rheumatologists, orthopaedic surgeons
and physiotherapists). Potential participants will first
Chang W-J, et al. BMJ Open 2022;12:e062577. doi:10.1136/bmjopen-2022-062577
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Figure 1

Study flow chart. rTMS, repetitive transcranial magnetic stimulation.

complete an eligibility screening questionnaire. Those
who meet the eligibility criteria will be contacted by one
of the researchers to confirm their willingness to participate in the study and to arrange the baseline assessment
of outcomes. Participants will provide written informed
consent to the outcome assessor on arrival for the baseline assessment.
Randomisation allocation concealment and blinding
Participants will be randomly allocated to either: (1)
active rTMS+exercise or (2) sham rTMS+exercise, based
on a 1:1 allocation ratio. The randomisation schedule will
be generated by computer and a researcher not involved
in recruitment, treatment provision or assessment. The
randomisation schedule will be concealed in consecutively numbered, sealed opaque envelopes and given to
the researcher who delivers rTMS intervention. Participants will be blinded to the type of rTMS they will receive
and the study hypotheses. All participants will be given
the same instructions and information about the rTMS
intervention. Researchers conducting laboratory-
based
outcome assessment and physiotherapists providing exercise intervention will be blinded to group allocation.
Unblinding will be allowed when an adverse or unexpected event occurs.
Outcome measurements
Measures of feasibility and safety
Feasibility and safety of the rTMS and exercise intervention will be assessed using the following measures: (1)
the number of sessions attended by each participant
(attendance rate >80% is considered feasible);36 (2) the
number of dropouts in each group (dropout rate <20% is
considered feasible);36 (3) the proportion of participants
recruited from the total number screened; (4) willingness
of each participant to undergo therapy at baseline on an
11-point NRS with ‘not at all willing’ at 0 and ‘very willing’
Chang W-J, et al. BMJ Open 2022;12:e062577. doi:10.1136/bmjopen-2022-062577

at 10 (80% of participants score 7 or more are considered
feasible); (5) success of participant/outcome assessor/
therapist blinding; (6) the number of adverse events
and the details of each event.27 Each adverse event will
be considered separately. One or more serious adverse
events will be considered unsafe. The success of participant blinding will be assessed at the completion of the
intervention using a yes/no response to the question “Do
you believe you received real brain stimulation?” and an
11-point NRS of the individual’s confidence in that judgement. Participants will also be asked “Why do you believe
you received the real/sham brain stimulation?” and “Was
it divulged to you whether you were receiving real brain
stimulation or not?”27 Participant blinding will be considered successful if there is no difference between active
rTMS+exercise and sham rTMS+exercise groups in the
number of participants correctly guessing their treatment
allocation at the completion of the follow-up laboratory
assessment.37 The success of blinding of the outcome
assessor and treating physiotherapists will be determined
at the completion of the follow-up assessment using a
yes/no response to the question “Did you know which
intervention group the participant was assigned to before
completion of the follow-
up laboratory assessment?”
and “If you answer ‘yes’, how was it divulged to you?”27
Blinding of the outcome assessor and treating physiotherapists will be considered successful if they answer ‘no’ to
the first question.
Measures of pain and function
Knee pain and function will be assessed using: (1) an
11-point NRS for pain when walking in the past week;38
(2) the Western Ontario and McMaster Universities
Osteoarthritis Index (24 items, total score=96) (Likert
V.3.1) and its pain subscale (7 items, total score=28) and
physical function subscale (17 items, total score=68), a
3
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valid, reliable and responsive instrument for knee osteoarthritis;39 (3) the Global Perceived Effect Scale, where
each participant will rate their perceived response to treatments on a 7-point Likert scale ranging from ‘completely
recovered’ to ‘vastly worsened’;40 (4) modified painDETECT questionnaire (7 items, total score=38), a simple,
reliable and valid screening tool to detect a neuropathic
pain component in patients with knee osteoarthritis;41 42
(5) the number of painful sites, measured by participants
indicating the number of painful sites outside of the
affected knee lasting >24 hours in the past week on a
four-sided body map (total score=35) with higher scores
indicating more widespread hyperalgesia43 and (6) the
Pain Catastrophising Scale (13 items, total score=52), a
reliable and valid, 13-item self-report instrument to assess
patients’ thoughts and feelings about pain in the domains
of magnification, rumination and helplessness.44
To assess the long-
term effects of the intervention,
pain and function will also be assessed 3 months after the
completion of intervention via an electronic version of
these questionnaires.
Measures of physiological mechanisms
Measures of physiological mechanisms will be conducted
in the same order for each participant.
1. M1 organisation and function will be measured using
an established TMS mapping procedure.45 Participants
will be seated in a comfortable chair. Electromyography
(EMG) of the quadriceps muscles will be recorded
using bipolar surface electrodes (Ag-AgCl, Noraxon
dual electrodes). The active electrode will be placed
over the belly of the rectus femoris (RF), vastus lateralis (VL) and vastus medialis oblique (VMO) muscles
and the ground electrode placed at the tibial shaft.
EMG signals will be amplified (2000×) and filtered
(20–1000 Hz), and digitally sampled at 2000 Hz using
a Power 1902 Data Acquisition System and Spike2 software (CED, Cambridge, UK).
Single-pulse TMS delivered over M1 induces a magnetic
field over the participant’s scalp that evokes an electrical current in the underlying M1 tissue resulting in
muscle activation recorded as motor evoked potentials
(MEPs) using EMG. The scalp site evoking the largest
MEP (termed the ‘hotspot’, the coil position inducing a
maximal peak-to-peak MEP amplitude) for the RF muscle
at a given TMS intensity will be identified.46 The TMS
motor threshold assessment tool will be used to determine the active motor threshold (aMT),47 defined as
the minimum intensity required to evoke a reliable MEP
while participants maintained a muscle contraction of
10% averaged root mean square (RMS) EMG of three, 3 s
maximal muscle contractions of the RF muscle.
During TMS mapping, 126 single-
pulse biphasic
stimuli (2 s interstimulus interval) will be delivered pseudorandomly to the scalp over a 6×7 cm (7 rows and 8
columns) grid oriented to the hotspot at 120% aMT of
the RF muscle (Magstim Rapid2/70 mm figure-of-eight
coil; Magstim, UK). Participants will be asked to activate

the RF muscle to 10% of their EMG recorded during a
maximum voluntary contraction (determined as 10% of
the highest RMS EMG for 1 s during three, 3 s maximal
muscle contractions performed against manual resistance in sitting) with feedback provided on a monitor.
The coil will be placed tangentially to the skull with the
handle pointing laterally 90 degrees to induce a current
in the lateral-to-medial direction. The Neural Navigator
(Neurosoft, Russia) will be used to track the positions of
the TMS coil and participant’s head. To minimise muscle
fatigue, stimuli will be delivered in trains of seven stimuli.
The neuronavigational display is monitored to ensure
adequate coverage of the grid and that adjacent positions
not stimulated consecutively.
Maps for each of the RF, VL and VMO muscles will
be produced offline using a custom MATLAB script
(MathWorks, USA) according to previously published
methods.48 49 RMS amplitude of EMG traces of the MEPs
will be extracted from a 20–50 ms window after stimulation and background RMS EMG (55–5 ms prior to stimulation) will be subtracted.12 13 A surface map within a
transformed plane encompassing stimulation coordinates
and their corresponding MEP amplitude will be generated. The map will then be divided into 2744 partitions
(49×56), with each partition assigned an estimated MEP
amplitude based on the nearest acquired MEP values
using triangular linear interpolation. Partitions with MEP
amplitudes >10% of the maximum MEP amplitude will
be considered as active.48 Map volume is calculated as the
sum of MEP amplitudes of all active partitions to index
M1 corticomotor excitability.
2. Voluntary activation of the quadriceps muscles will be
measured using a twitch interpolation technique when
participants are seated with the hips and knees in 90
degrees flexion. A force increment will be recorded
using a force transducer when an electrical stimulus
delivered by a constant current stimulator (Digitimer,
DS7AH) to the femoral nerve 1–2 s into the maximal
muscle contraction (superimposed twitch), and again
3–4 s afterward when the muscles are at rest (control
twitch). Voluntary activation (%)=[1−(superimposed
twitch/control twitch)]×100.50
3. Pressure pain thresholds (PPTs) will be measured using a hand-held pressure algometer (Somedc, Hörby, Sweden, probe size 1 cm2) to quantify mechanical
sensitivity. The probe (size 1 cm2) will be applied perpendicular to the skin (rate 40 kPa/s) until the participant first reports that the sensation of pressure has
changed to pain. PPTs will be measured at the side of
the knee joint line of the most painful knee and ipsilateral thumbnail. The average of three measurements
at each site will be used in the analysis. PPT measures
have been shown to be reliable in knee osteoarthritis
(intraclass correlation coefficient (ICC)=0.83 (95% CI
0.72 to 0.90)).51
4. Conditioned pain modulation (CPM) is a well-
established, reliable and safe measure of pain processing that is thought to reflect endogenous pain
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inhibition. CPM is assessed as a change in the pain
perceived in one body site (test stimulation) as a result of pain induced in another body site (conditioned
stimulation). We will use PPT measured at the upper
trapezius muscle contralateral to the painful knee as
test stimulation7 and pain is induced in the ipsilateral
hand by cold pressor test (CPT) as conditioned stimulation. Three PPTs (test stimulation) will be measured
before CPT (conditioned stimulation). For CPT, participants will immerse the hand in the cold water (4°C)
for a maximum of 2 min.52 Participants can remove
their hand prior to the completion of CPT if the pain
becomes unbearable and a pain rating on an NRS (0–
100) will be obtained immediately after participants remove their hand. Three PPT measurements will then
be repeated when pain score reaches 50 out of 100 after CPT. A reduction in PPT indicates deficient endogenous pain inhibition. CPM paradigm has shown good
intrasession reliability (ICC >0.75).53
Intervention
Participants will be randomly allocated to either active
rTMS+exercise or sham rTMS+exercise intervention
groups. For participants with bilateral knee pain, the
most painful knee or the right knee if both knees are
equally painful, will be treated. All participants will
receive a total of 12 treatment sessions (two sessions per
week for 6 weeks). A systematic review recommended 12
supervised exercise sessions are needed to be effective
for improving pain and disability in knee osteoarthritis.54
Two qualified, registered physiotherapists with clinical
experience in treating knee osteoarthritis will provide
exercise therapy for all participants. A researcher trained
in the use of rTMS will deliver active and sham rTMS to
all participants according to their group allocation and
will not be blinded to group allocation. Participants will
be advised to continue with their usual medication during
the study. Medications for their knee pain will be recorded
at baseline and the follow-up laboratory assessment. Data
for the frequency of use (in the past 6 months at baseline
and during the 6-week intervention at follow-up) of pain
medications will be collected. For each session, participants will receive active or sham rTMS (15 min) followed
by supervised exercise (30 min).

intensity.56 For sham rTMS, a sham coil that looks identical to a real coil but produces only audible clicks and
no magnetic pulse will be used to deliver the stimulation protocol identical to the one used for active rTMS.
This is the most used sham rTMS protocol in controlled
trials.12 57 58
Exercise
Immediately after the rTMS intervention, participants
will receive one-
to-
one quadriceps strengthening exercise delivered by their treating physiotherapist. A standardised set of quadriceps strengthening exercises known
to be effective in knee osteoarthritis will be performed
using ankle cuff weights or resistance bands, and exercise intensity will be progressed by the physiotherapist as
appropriate for each participant (online supplemental
table S3).5 25 59 A home exercise programme will also be
developed and monitored by the physiotherapists for all
participants to perform two times a week during intervention. Participants will complete an exercise diary and
return to their treating physiotherapist weekly for compliance and adherence to their home exercise programme
and for recording any adverse effects of home exercise
(ie, whether pain was present, whether any exercises
were difficult, the reason why exercises were unable to be
completed if applicable).

Repetitive transcranial magnetic stimulation
For active rTMS, high-frequency rTMS will be applied to
the motor hotspot of the first dorsal interosseous muscle
ipsilateral to the treated knee using a Magstim Super
Rapid2 (Magstim) and a figure-of-eight air-cooled coil (70
mm). For each session, 3000 stimuli (10 Hz, 30 trains of
10 s, 20 s intertrain interval) will be delivered at 90% of
resting motor threshold (rMT).55 rMT is defined as the
minimum intensity at which 5 out of 10 stimuli, delivered
to the hotspot, evoked a peak-to-peak MEP of at least
50 µV.46 To account for any between-session change in
rMT, participants’ rMT will be assessed at the beginning
of each treatment session to determine the stimulation

Sample size and analysis
This is a pilot study designed to provide data to inform
a full randomised controlled trial should the intervention appear feasible, safe and show trends of efficacy.
Although a prospective sample size calculation is not
required in a pilot randomised controlled trial, 15–20
participants per intervention group is recommended in
pilot studies.60 61 We have selected a sample size of 15
participants per group, or total 30 participants as this
is achievable based on the successful completion of a
previous pilot study with a similar design by our group.27
Measures of feasibility and safety will be analysed
descriptively.62 Within-group changes will be calculated
as follow-up minus baseline (mean and SD). Two-sided
t-tests will be used for within-group comparisons between
baseline and follow-
up measures and effect sizes will
be calculated to indicate whether a full randomised
controlled trial will be worthwhile. An effect size of 0.5 for
pain and physical function outcomes is recommended for
knee osteoarthritis clinical trials.63 Due to the limitations
of performing statistical comparisons with a small sample
size and low power, statistical comparisons between
groups will not be conducted.64 Sample size calculation
for a full randomised controlled trial will be based on
the minimum clinically important difference (MCID) on
outcome measures of pain and function.64 The MCID in
knee osteoarthritis studies is a change in pain of 1.8 unit
(SD of 2.2) and a change in function of 6 units (SD of
9.7).65 Power will be set at 80% to detect between-group
differences, with an α of 0.05 and a dropout rate based on
that of the pilot trial.
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Patient and public involvement
We engaged a consumer representative form the Musculoskeletal Health Clinical Academic Group Consumer
Community Council, Australian & New Zealand Musculoskeletal Clinical Trial Network and received feedback on
the study including the proposed intervention and potential barriers to participant recruitment. The feedback
from the consumer representative has been addressed
and used to guide the design of intervention and recruitment strategies.

ETHICS, DATA SAFETY AND DISSEMINATION
This trial has been approved by the University of New
South Wales Human Research Ethics Committee
(HC210954), who may audit the study conduct during
the study or after completion. Any deviation from
protocol will require ethics amendment and be updated
to the registry. This study will be terminated if any serious
adverse event occurs. A serious adverse event is defined
as any untoward medical occurrence or effect that results
in death, or is life-threatening, requires hospitalisation,
results in significant or persistent disability. There will
not be a data monitoring committee due to the relatively
short duration of this pilot study.
Participants’ identifiers (ie, name, address, date of
birth, sex, profession) will be removed from the data.
Identifying information will be replaced with a unique
anonymous identification number based on the recruitment order. Each participant will be assigned an anonymous identification number. This will be used in all
further data recording and thus they will be de-identified.
Paperwork that links anonymous identification number
to participants’ names will be stored in a locked room. All
de-identified data that cannot be linked to an individual
participant will be stored electronically with password
protection. There is no perceived need to re-identify any
electronic data. Only aggregate results will be reported;
therefore, it will not be possible to identify individual
participants in any information reported or published
from this study. The data collected in hardcopy will be
retained for 15 years after publication and electronic data
will be stored for a minimum of 7 years.
Study results will be disseminated via presentations at
scientific meetings and publications in a peer-reviewed
journal. Publications and presentations related to
this study will be authorised and reviewed by all study
investigators.
Trial status
This trial will start recruiting in March 2022 and is
expected to be completed by March 2023.
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